Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + anti-PD(L)1 antibody (Eisai Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of lenvatinib, a multi-kinase inhibitor, and an anti-PD-1 or anti-PD-L1 monoclonal antibody. Lenvatinib inhibits vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), PDGFRα, KIT, and RET, thereby inhibiting angiogenesis and tumor cell proliferation. The addition of a PD-1/PD-L1 checkpoint inhibitor (such as pembrolizumab, nivolumab, or camrelizumab) aims to restore the anti-tumor immune response by preventing the interaction between PD-1 on T-cells and PD-L1 on tumor cells. This specific regimen, often combined with Drug-Eluting Beads Transarterial Chemoembolization (DEB-TACE), is being investigated by Dr. Ze-yang Ding for the downstaging of advanced intrahepatic cholangiocarcinoma to enable radical surgical interventions.
- Other names
- lenvatinib plus anti-PD-1/PD-L1DEB-TACE + lenvatinib + anti-PD(L)1envatinib plus anti-PD(L)1
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on lenvatinib + anti-PD(L)1 antibody (Eisai Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + anti-PD(L)1 antibody (Eisai Co., Ltd.).